SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
The Allstate Corporation (ALL-PG) trades at a trailing P/E of 0.7. Trailing earnings yield is 153.85%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (0.7); PEG ≤ 1.0 — Peter Lynch undervalued (0.01); earnings yield beats bond yields (153.85%).
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 153.85% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 66/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ALL-PG
Valuation Multiples
P/E (TTM)0.7
Forward P/EN/A
PEG Ratio0.01
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.10
EV/EBITDA0.0
Per Share Data
EPS (TTM)$38.19
Book Value / Share$0.00
Revenue / Share$251.08
FCF / Share$0.00
Yields & Fair Value
Earnings Yield153.85%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$4.67 |
$37.4B |
$1.88B |
5% |
| 2017 |
$9.35 |
$39.41B |
$3.55B |
9% |
| 2018 |
$6.12 |
$39.82B |
$2.16B |
5.4% |
| 2019 |
$14.03 |
$41.4B |
$4.85B |
11.7% |
| 2020 |
$17.31 |
$41.93B |
$5.58B |
13.3% |
| 2021 |
$17.25 |
$50.65B |
$1.61B |
3.2% |
| 2022 |
$-5.03 |
$51.6B |
$-1.29B |
-2.5% |
| 2023 |
$-1.20 |
$57.09B |
$-188M |
-0.3% |
| 2024 |
$16.99 |
$64.12B |
$4.67B |
7.3% |
| 2025 |
$38.19 |
$66.46B |
$10.28B |
15.5% |
